ClinicalTrials.gg
TerminatedNCT02928289Updated Nov 14, 2025Results posted

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

An interventional study of VISCO360 ab interno canaloplasty surgery and Selective Laser Trabeculoplasty (SLT) in Open-Angle Glaucoma, sponsored by Sight Sciences, Inc.. Terminated at 6 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Poor enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. — none open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Sight Sciences, Inc..

Started
2017
the only one that year
No phase
7 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc., this one is the only one that started in 2017, is one of 7 with no phase, and was the 1st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.

Read the detailed description

This is a randomized study comparing viscodilation with the VISCO360 device to selective laser trabeculoplasty. Subjects with mild to moderate primary open-angle glaucoma undergo IOP-lowering medication washout at baseline and at Month 12. Subjects will be followed through Month 24.

03

Conditions studied

  • Open-Angle Glaucoma

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with primary open-angle glaucoma (POAG) in the study eye.
  • Pseudophakic with Posterior Chamber IOL (PCIOL)
  • Able and willing to attend follow up visits for two years post-operative
  • Able and willing to sign

Exclusion criteria

Exclusion Criteria:

  • Phakia or aphakia
  • Previous glaucoma procedure with or without an implantable glaucoma device (including incisional surgery, , iridectomy/iridotomy, etc.) [Subjects with one prior SLT application (>3 months prior to screening) or prior ECP (performed > 12 months prior to screening) can be enrolled].
  • Use of more than 3 ocular hypotensive medications (combination medications count as 2 medications)
  • Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic, pseudoexfoliative, pigmentary or neovascular glaucoma
  • Abnormal angle anatomy as determined by gonioscopy (e.g. peripheral anterior synechiae, rubeosis or other angle abnormalities)
  • Participation in any clinical trial ≤ 30 days prior to screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    VISCO360 ab interno canaloplasty surgery

    Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).

    Device: VISCO360 ab interno canaloplasty surgery

  • Active comparator
    Selective Laser Trabeculoplasty (SLT)

    Subjects randomized to this arm will undergo the SLT procedure.

    Device: Selective Laser Trabeculoplasty (SLT)

Interventions

  • DeviceVISCO360 ab interno canaloplasty surgery

    360 degrees of viscodilation of Schlemm's canal

  • DeviceSelective Laser Trabeculoplasty (SLT)

    360 degrees of selective laser trabeculoplasty

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg)

    The mean of the difference between the baseline DIOP and the 12 month DIOP for each subject. Measurements at baseline and 12 months are following wash-out of glaucoma medication.

    Time frame: 12 months

Secondary outcomes

  1. Proportion of Subjects Achieving a ≥ 20% Change in Mean Diurnal IOP at 12 Months

    Measurement is performed at 12 months following wash-out of glaucoma medication and is the number of subjects with 12 month DIOP that is at least 20% lower than the baseline DIOP divided by the number of subjects and multiplied by 100.

    Time frame: 12 months

07

Results

Posted Sep 24, 2025

Participant flow

Twenty-nine potential subjects provided written informed consent, however only 17 met eligibility criteria and were then randomized and treated.

Participant flow — Overall Study
MilestoneVISCO360 ab interno canaloplasty surgerySelective Laser Trabeculoplasty (SLT)
Started710
Completed00
Not completed710

Outcome measures

PrimaryMean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg)

The mean of the difference between the baseline DIOP and the 12 month DIOP for each subject. Measurements at baseline and 12 months are following wash-out of glaucoma medication.

Time frame:
12 months
Reported as:
Mean · mm Hg
Mean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg)
mm HgVISCO360 ab interno canaloplasty surgerySelective Laser Trabeculoplasty (SLT)
Mean Change From Baseline in Diurnal IOP at 12 Months (Measured in mm Hg)-5.2 ± 7.6-3.6 ± 3.3
SecondaryProportion of Subjects Achieving a ≥ 20% Change in Mean Diurnal IOP at 12 Months

Measurement is performed at 12 months following wash-out of glaucoma medication and is the number of subjects with 12 month DIOP that is at least 20% lower than the baseline DIOP divided by the number of subjects and multiplied by 100.

Time frame:
12 months
Reported as:
Count of participants · Participants
Proportion of Subjects Achieving a ≥ 20% Change in Mean Diurnal IOP at 12 Months
ParticipantsVISCO360 ab interno canaloplasty surgerySelective Laser Trabeculoplasty (SLT)
Proportion of Subjects Achieving a ≥ 20% Change in Mean Diurnal IOP at 12 Months21

Adverse events

Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VISCO360 ab interno canaloplasty surgery1/7 (14.3%)1/7 (14.3%)1/7 (14.3%)
Selective Laser Trabeculoplasty (SLT)0/10 (0%)2/10 (20%)4/10 (40%)
Most frequent serious events
Most frequent serious events
EventVISCO360 ab interno canaloplasty surgerySelective Laser Trabeculoplasty (SLT)
non-ocularCardiac disorders1/70/10
Ocular adverse eventEye disorders0/71/10
non-ocularCardiac disorders0/71/10
Most frequent other events
Most frequent other events
EventVISCO360 ab interno canaloplasty surgerySelective Laser Trabeculoplasty (SLT)
Ocular adverse eventsEye disorders1/70/10
ocular adverse eventEye disorders0/71/10
non-ocular adverse eventRespiratory, thoracic and mediastinal disorders0/71/10
non ocular adverse eventGeneral disorders0/71/10
ocular adverse eventEye disorders0/71/10
ocular adverse eventEye disorders0/71/10
non ocular adverse eventGeneral disorders0/71/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)VISCO360 ab Interno Canaloplasty SurgerySelective Laser Trabeculoplasty (SLT)Total
Mean76.1 ± 6.774.7 ± 11.575.4 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)VISCO360 ab Interno Canaloplasty SurgerySelective Laser Trabeculoplasty (SLT)Total
Female369
Male448
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VISCO360 ab Interno Canaloplasty SurgerySelective Laser Trabeculoplasty (SLT)Total
Hispanic or Latino325
Not Hispanic or Latino4812
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VISCO360 ab Interno Canaloplasty SurgerySelective Laser Trabeculoplasty (SLT)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White3811
More than one race000
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(Participants)VISCO360 ab Interno Canaloplasty SurgerySelective Laser Trabeculoplasty (SLT)Total
United States71017
Diurnal Intraocular Pressure
Diurnal Intraocular Pressure(mm Hg)VISCO360 ab Interno Canaloplasty SurgerySelective Laser Trabeculoplasty (SLT)Total
Mean25.8 ± 4.325.1 ± 2.525.4 ± 3.2
08

Study locations

6 sites
  • Vold Vision
    Fayetteville, Arkansas 72704, United States
  • Coastal Vision Medical Group
    Orange, California 92868, United States
  • Dean McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • El Paso Eye Surgeons
    El Paso, Texas 79902, United States
  • Ophthalmology Associates
    Fort Worth, Texas 76102, United States
09

References and documents

Publications

  • Rolim-de-Moura CR, Paranhos A Jr, Loutfi M, Burton D, Wormald R, Evans JR. Laser trabeculoplasty for open-angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2022 Aug 9;8(8):CD003919. doi: 10.1002/14651858.CD003919.pub3. PubMed 35943114 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Jan 2019, 23 months.

Results were first posted in Sep 2025, 6 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2016
First posted
Oct 10, 2016
StartActual
Jan 23, 2017
Primary completionActual
Jan 17, 2019
CompletionActual
Jan 17, 2019
Results first posted
Sep 24, 2025
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02928289
Lead sponsor
Sight Sciences, Inc.
Responsible party
Sponsor
First posted
Oct 10, 2016
Start date
Jan 23, 2017
Primary completion
Jan 17, 2019
Completion
Jan 17, 2019
Results posted
Sep 24, 2025
Last update
Nov 14, 2025

Study contacts

Anne-Marie Ripley
study director · Sight Sciences, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion